Wide-Area Transepithelial Tissue Sampling with Computer-Assisted 3D Analysis (WATS3D) - (0578) — MM 0578 | CIGNA Coverage Update

Cigna modified MM 0578 for WATS3D (wide-area transepithelial tissue sampling with computer-assisted 3D analysis), effective December 16, 2025. Here's what billing teams need to do.

Cigna Healthcare updated its coverage policy for WATS3D under policy code MM 0578. This procedure is used during endoscopy to sample esophageal tissue for Barrett's esophagus detection and surveillance. The update affects five pathology and cytopathology CPT codes — 88104, 88112, 88305, 88312, and 88361 — and billing teams need to review their charge capture and documentation workflows before December 16, 2025.

Quick-Reference Table

Cigna WATS3D Coverage Criteria and Medical Necessity Requirements 2025

The Cigna WATS3D coverage policy addresses a specific clinical question: when is this esophageal sampling technique covered, and when does it cross into experimental territory? That line matters enormously for your reimbursement on the pathology codes that ride with this procedure.

WATS3D is proposed as an endoscopic method for sampling esophageal tissue. Its primary clinical application is the detection and surveillance of Barrett's esophagus. Barrett's esophagus is a condition where chronic acid reflux causes abnormal cell changes in the esophageal lining — changes that carry cancer risk and require ongoing monitoring.

The coverage policy under MM 0578 is the governing document for whether Cigna pays for the downstream pathology work when WATS3D is used. That downstream work is where your billing exposure lives. CPT 88305 (Level IV surgical pathology) and CPT 88104 (cytopathology, fluids, washings, or brushings) are the codes most likely to appear on claims tied to this procedure. If the medical necessity criteria aren't met, those claims get denied — not just the procedure itself.

The policy does not address prior authorization requirements. Consult your Cigna contract and provider agreement separately.

Cigna WATS3D Exclusions and Non-Covered Indications

The policy specifically frames WATS3D as a proposed endoscopic sampling method. That word — proposed — signals where Cigna draws the line.

When a payer calls something "proposed," they're flagging that the clinical evidence isn't settled enough to support broad coverage. The procedure may be used in practice, but payer coverage lags clinical adoption.

For billing purposes, this means claims for WATS3D-associated pathology codes that lack strong documentation of clinical indication carry high denial risk. You can't assume coverage just because the physician performed the procedure.

As a general billing best practice — not a requirement stated in MM 0578 — document the Barrett's esophagus indication clearly and document why WATS3D was chosen over standard biopsy. If your practice uses CPT 88361 (morphometric analysis, tumor immunohistochemistry) or CPT 88312 (special stain including interpretation and report, Group I for microorganisms) alongside WATS3D, those codes require tight documentation. They're downstream of the tissue sample and have narrower clinical indications than CPT 88305 or 88104.

Coverage Indications at a Glance

Cigna WATS3D Billing Guidelines and Action Items 2025

CPT, HCPCS, and ICD-10 Codes for WATS3D Under MM 0578

The policy data for MM 0578 includes five CPT codes. All five are pathology and cytopathology codes — none are the procedure code for WATS3D itself. This is common for policies that address tissue sampling: the payer defines coverage through the downstream analytical work, not just the collection method.

No HCPCS Level II codes and no ICD-10-CM codes appear in the current policy data for MM 0578. For ICD-10 guidance on Barrett's esophagus diagnoses, work with your gastroenterology coder — the policy itself does not define covered diagnoses.

CPT Codes Under MM 0578

A Note on Code Selection

CPT 88305 is the workhorse here — Level IV surgical pathology covers the gross and microscopic examination that Barrett's surveillance requires. CPT 88312 and 88361 are codes for specialized staining and morphometric analysis. Those two have narrower clinical indications and are more likely to face scrutiny on a medical necessity review.

Don't bill all five codes reflexively on every WATS3D case. Bill what was actually performed and documented. Stacking pathology codes without documentation support is the fastest way to trigger a claim denial and a follow-up audit.